Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (18952)	3/23/2004 12:37:05 PM
From: John Carragher	Read Replies (1) \| Respond to of 78710

you may want to check out adlr. snip from yahoo message board thread. given that there is no FDA approved drug for POI or OBD available and Adolor and GSK have generated data that show benefits for this condition, Entereg has value as a treatment that can facilitate patient recovery and reduce health-care costs. In addition, the new medications is a much needed treatment for chronic pain patients as well as terminally ill patients who go through living inhumane hell due to Opiate-Induced Bowel Disfunction (OBD). Why not approve a safe medication that will allow OBD patients to stay pain free, as opposed to stop taking their pain medications due to ill effects due to OBD --- these are the baby boomers parents, and/or the baby boomers themselves --- you better pray that you are not caught in that inhumane situation. I believe it had a high of about twenty early this year but the method they used to pass phase 111 objectives ended up with mixed results and lower than was needed to qualified. Yet, company was approved about six weeks ago for fast track and continues to prepare papers for fda approval on this drug. Drug shows up to one day or more in early release of patients. Dr.s can administer move drug pain killing meds as this drug offset bowl constipation. fyi I believe it could be back up to 18 or so from below 15. here.